PMC Links for Nucleotide (Select 1519315674) - PMC

Select item 60584941.

Dipeptide-modified nanoparticles to facilitate oral docetaxel delivery: new insights into PepT1-mediated targeting strategy

Yuqian Du, Chutong Tian, Menglin Wang, Di Huang, Wei Wei, Yan Liu, Lin Li, Bingjun Sun, Longfa Kou, Qiming Kan, Kexin Liu, Cong Luo, Jin Sun, Zhonggui He

Drug Deliv. 2018; 25(1): 1403–1413. Published online 2018 Jun 12. doi: 10.1080/10717544.2018.1480675

PMCID:: PMC6058494

Abstract Article PDF–1.6M

Select item 57263732.

Regulation profile of the intestinal peptide transporter 1 (PepT1)

Chun-Yang Wang, Shu Liu, Xiao-Nv Xie, Zhi-Rong Tan

Drug Des Devel Ther. 2017; 11: 3511–3517. Published online 2017 Dec 8. doi: 10.2147/DDDT.S151725

PMCID:: PMC5726373

Abstract Article PDF–245K

Select item 48216913.

Species Differences in the Pharmacokinetics of Cefadroxil as Determined in Wildtype and Humanized PepT1 Mice

Yongjun Hu, David E. Smith

Biochem Pharmacol. Author manuscript; available in PMC 2017 May 1.

Published in final edited form as: Biochem Pharmacol. 2016 May 1; 107: 81–90. Published online 2016 Mar 12. doi: 10.1016/j.bcp.2016.03.008

PMCID:: PMC4821691

Abstract Article PDF–1.4M

Select item 47147434.

A new target ligand Ser–Glu for PEPT1-overexpressing cancer imaging

Tongcheng Dai, Na Li, Lingzhi Zhang, Yuanxing Zhang, Qin Liu

Int J Nanomedicine. 2016; 11: 203–212. Published online 2016 Jan 11. doi: 10.2147/IJN.S97207

PMCID:: PMC4714743

Abstract Article PDF–2.4M

Select item 54950345.

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events

Tobias Meißner, Adam Mark, Casey Williams, Wolfgang E. Berdel, Stephanie Wiebe, Andrea Kerkhoff, Eva Wardelmann, Timo Gaiser, Carsten Müller-Tidow, Philip Rosenstiel, Norbert Arnold, Brian Leyland-Jones, Andre Franke, Martin Stanulla, Michael Forster

Cold Spring Harb Mol Case Stud. 2017 Jul; 3(4): a001677. doi: 10.1101/mcs.a001677

PMCID:: PMC5495034

Abstract Article PDF–2.3M

Select item 52675156.

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1

Y. Anne Pak, Amanda J. Long, William F. Annes, Jennifer W. Witcher, Mary Pat Knadler, Mosun A. Ayan-Oshodi, Malcolm I. Mitchell, Phillip Leese, Kathleen M. Hillgren

Drug Metab Dispos. 2017 Feb; 45(2): 137–144. Published online 2017 Feb. doi: 10.1124/dmd.116.071118

PMCID:: PMC5267515

Abstract Article PDF–840K

Select item 40551447.

Gene markers of cellular aging in human multipotent stromal cells in culture

Ian H Bellayr, Jennifer G Catalano, Samir Lababidi, Amy X Yang, Jessica L Lo Surdo, Steven R Bauer, Raj K Puri

Stem Cell Res Ther. 2014; 5(2): 59. Published online 2014 Apr 28. doi: 10.1186/scrt448

PMCID:: PMC4055144

Abstract Article PDF–3.2M

Select item 36028068.

Proton-coupled oligopeptide transporter family SLC15: Physiological, pharmacological and pathological implications

David E. Smith, Benjamin Clémençon, Matthias A. Hediger

Mol Aspects Med. Author manuscript; available in PMC 2014 Apr 1.

Published in final edited form as: Mol Aspects Med. 2013 Apr; 34(2-3): 323–336. doi: 10.1016/j.mam.2012.11.003

PMCID:: PMC3602806

Abstract Article PDF–2.0M

Select item 31991589.

Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA–induced fluorescence

Kenkichi Takahashi, Naokado Ikeda, Naosuke Nonoguchi, Yoshinaga Kajimoto, Shin-Ichi Miyatake, Yuichiro Hagiya, Shun-Ichiro Ogura, Hiroshi Nakagawa, Toshihisa Ishikawa, Toshihiko Kuroiwa

Neuro Oncol. 2011 Nov; 13(11): 1234–1243. Published online 2011 Aug 8. doi: 10.1093/neuonc/nor116